RxDoctor Payments Data

Laura Rodriguez

Family · San Antonio, TXNPI 1336591205

Payments from drug & device makers

$1,178in general payments, 2019–2025

Across 62 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$338
  • Pfizer$196
  • Novartis$173
  • Biohaven Pharmaceuticals, Inc.$168
  • Novo Nordisk$117
  • Boston Scientific$71
  • plus $115 from 5 others

What the payments were for

  • Food & beverage$1,178100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,178 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$25,117
Medicare patients
72
Services billed
500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$71,609
FarxigaDapagliflozin Propanediol53$55,442
TrulicityDulaglutide36$48,649
MounjaroTirzepatide29$30,824
JardianceEmpagliflozin11$18,780
Repatha SureclickEvolocumab26$13,993
MyrbetriqMirabegron17$12,083
Tresiba Flextouch U-200Insulin Degludec11$9,523
Repatha SyringeEvolocumab12$6,860
Duloxetine Hcl55$1,810
Gabapentin56$1,632
Albuterol Sulfate HfaAlbuterol Sulfate68$1,549
Atorvastatin Calcium148$1,138
Omeprazole57$1,125
Fluticasone Propionate68$793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$117$71,60960 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →